|
Allergan, Inc. Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine
First and Only Hyaluronic Acid Filler Approved to Last up to One Year from Initial Treatment Now Available with Lidocaine Providing Patients a More Comfortable Injection Experience.
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) today announced the U.S. Food and Drug Administration’s (FDA) approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement1 in hyaluronic acid (HA) dermal fillers. Allergan’s new JUVÉDERM® formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or “parentheses”) that appear around the nose and mouth. JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2 and number-one selling hyaluronic acid dermal filler.
Read more of this article...
|
|
